The National Institutes of Health has awarded the Icahn School of Medicine at Mount Sinai an $8.5 million renewal grant to ...

Nuevocor, a global biotechnology company, today announced the appointment of Al Gianchetti as Chief Executive Officer (CEO) and member of the Board of Directors. Nuevocor develops novel therapies for ...

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by using the patient's own T-cells to target tumors.

A new study from Karolinska University Hospital and Karolinska Institutet in collaboration with Uppsala University Hospital ...

Corsera, which emerged in September 2025, aims to extend healthspan by reducing the risk of atherosclerotic cardiovascular ...